A retrospective cohort study of Epstein-Barr virus infection status and systemic lupus erythematosus
© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR)..
OBJECTIVES: Systemic lupus erythematosus (SLE) and the Epstein-Barr virus (EBV) are very closely related. This study estimated the impact of EBV infection status on clinical manifestations and disease remission in patients with SLE.
METHOD: A retrospective study was performed using electronic health records of patients with SLE. The SLE disease activity index (SLEDAI-2 K) was used to assess disease activity. VCAIgM or EAIgM positive or EBVDNA copies ≥ 50 IU/mL were defined as lytic infection group, EBNA-IgG or VCAIgG-positive and who were negative for both VCAIgM and EAIgM with EBVDNA copies < 50 IU/mL were defined as the latent infection group. The endpoint (disease remission) was defined as a decrease in SLEDAI-2 K score of ≥ 1 grade or ≥ 4 points from baseline. The association between EBV infection status and disease remission was assessed using propensity score weighting and multivariable Cox regression models.
RESULTS: There were 75 patients with SLE in the EBV lytic infection group and 142 patients in the latent infection group. The SLEDAI-2 K score was higher in the lytic infection group (10.00 (6.25, 16.00) vs. 8.00 (5.00, 10.00), Z = 3.96, P < 0.001). There was a significant difference in the effect of EBV lytic infection on disease remission compared to latent infection (HR 0.30, 95% CI 0.19-0.49, P < 0.001).
CONCLUSIONS: Patients with SLE with lytic EBV infection have higher disease activity and take longer to achieve remission. Our study furthers our understanding of the relationship between SLE and EBV infection and may inform better treatment practices in the future.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
---|---|
Enthalten in: |
Clinical rheumatology - 43(2024), 5 vom: 15. Apr., Seite 1521-1530 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chen, Mengjie [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Viral |
---|
Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10067-024-06917-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36998823X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM36998823X | ||
003 | DE-627 | ||
005 | 20240416232749.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240322s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10067-024-06917-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1377.xml |
035 | |a (DE-627)NLM36998823X | ||
035 | |a (NLM)38509241 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chen, Mengjie |e verfasserin |4 aut | |
245 | 1 | 2 | |a A retrospective cohort study of Epstein-Barr virus infection status and systemic lupus erythematosus |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 16.04.2024 | ||
500 | |a Date Revised 16.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR). | ||
520 | |a OBJECTIVES: Systemic lupus erythematosus (SLE) and the Epstein-Barr virus (EBV) are very closely related. This study estimated the impact of EBV infection status on clinical manifestations and disease remission in patients with SLE | ||
520 | |a METHOD: A retrospective study was performed using electronic health records of patients with SLE. The SLE disease activity index (SLEDAI-2 K) was used to assess disease activity. VCAIgM or EAIgM positive or EBVDNA copies ≥ 50 IU/mL were defined as lytic infection group, EBNA-IgG or VCAIgG-positive and who were negative for both VCAIgM and EAIgM with EBVDNA copies < 50 IU/mL were defined as the latent infection group. The endpoint (disease remission) was defined as a decrease in SLEDAI-2 K score of ≥ 1 grade or ≥ 4 points from baseline. The association between EBV infection status and disease remission was assessed using propensity score weighting and multivariable Cox regression models | ||
520 | |a RESULTS: There were 75 patients with SLE in the EBV lytic infection group and 142 patients in the latent infection group. The SLEDAI-2 K score was higher in the lytic infection group (10.00 (6.25, 16.00) vs. 8.00 (5.00, 10.00), Z = 3.96, P < 0.001). There was a significant difference in the effect of EBV lytic infection on disease remission compared to latent infection (HR 0.30, 95% CI 0.19-0.49, P < 0.001) | ||
520 | |a CONCLUSIONS: Patients with SLE with lytic EBV infection have higher disease activity and take longer to achieve remission. Our study furthers our understanding of the relationship between SLE and EBV infection and may inform better treatment practices in the future | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Epstein-Barr virus | |
650 | 4 | |a SLEDAI-2 K | |
650 | 4 | |a Systemic lupus erythematosus | |
650 | 4 | |a Therapy | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
700 | 1 | |a Tu, Jianxin |e verfasserin |4 aut | |
700 | 1 | |a Huang, Mingyu |e verfasserin |4 aut | |
700 | 1 | |a Cheng, Yongjun |e verfasserin |4 aut | |
700 | 1 | |a Sun, Li |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 43(2024), 5 vom: 15. Apr., Seite 1521-1530 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
773 | 1 | 8 | |g volume:43 |g year:2024 |g number:5 |g day:15 |g month:04 |g pages:1521-1530 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-024-06917-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 43 |j 2024 |e 5 |b 15 |c 04 |h 1521-1530 |